Contact: Eileen Teves, 210-450-7239, tevese@uthscsa.edu
Content provided by Claire Kowalick
SAN ANTONIO – A pilot study led by scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) shows promise for people with mild cognitive changes treated with lamivudine, a Food and Drug Administration-approved antiretroviral drug. The study reveals significant improvement in neurodegeneration and inflammation.
Lamivudine is an antiviral medicine that prevents human immunodeficiency virus (HIV) or hepatitis B virus from multiplying in the body.
Scientists from UT Health San Antonio’s Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases and the Sam and Ann Barshop Institute for Longevity and Aging Studies developed the clinical trial to see if the drug could benefit people with cognitive impairment.
“It’s an exciting time for Alzheimer’s disease research with many promising trials coming out,” said A. Campbell Sullivan, PsyD, ABPP-CN, clinical associate professor in the department of neurology at the Biggs Institute and the study’s co-principal investigator. “Disease-modifying treatments for dementia are limited and can have worrisome side effects. Our results show that treatment with lamivudine was safe and suggest a beneficial effect for those with early Alzheimer’s disease.”
The study included 12 participants, aged 52 to 83 years old, with mild cognitive impairment. They were placed on lamivudine for six months with blood and cerebrospinal fluid collected at baseline and following discontinuation of treatment to study biomarkers. Cerebrospinal fluid is the liquid around the brain and spinal cord. The fluid serves as cushion for the brain and spinal cord and helps doctors identify or rule out various diseases.
Designed to evaluate the safety and feasibility of using antiretroviral therapy for Alzheimer’s disease, the study surprised researchers because they were able to find significant improvement in two markers of neurodegeneration and the reduction of inflammation. This provided encouraging results that they hope to explore in future studies.
Antiviral drugs like lamivudine stop the virus from replicating and inserting itself into the genome. In Alzheimer’s disease, lamivudine may stop the activation of retrotransposons, which the body views as an endogenous virus.
Over the past few decades, Sullivan said there has been exciting developments in biomarker identification and brain imaging, meaning they can detect problems earlier, especially in patients with a genetic predisposition for the condition. When detected early, problems may be kept at bay longer or possibly prevented from developing.
To read more about the study, visit: Antiretroviral drug shows potential for Alzheimer’s disease treatment in early clinical trials – UT Health San Antonio (uthscsa.edu)
The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is one of the country’s leading health science universities and is designated as a Hispanic-Serving Institution by the U.S. Department of Education. With missions of teaching, research, patient care and community engagement, its schools of medicine, nursing, dentistry, health professions, graduate biomedical sciences and public health have graduated more than 43,886 alumni who are leading change, advancing their fields and renewing hope for patients and their families throughout South Texas and the world. To learn about the many ways “We make lives better®,” visit UTHealthSA.org.
Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube.
The Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases is dedicated to providing comprehensive dementia care while advancing treatment through clinical trials and research. The Biggs Institute is a National Institute on Aging (NIA)-designated Alzheimer’s Disease Research Center (ADRC). In addition to patient care and research, the Biggs Institute partners with the School of Nursing at UT Health Science Center San Antonio to offer the Caring for the Caregiver program.
The Sam and Ann Barshop Institute for Longevity and Aging Studies is one of the world’s premier institutes dedicated to the study of age-related diseases. The Barshop Institute is the only aging-intensive research institute in the country to have four peer-reviewed designations: two National Institute on Aging (NIA)-funded centers (Nathan Shock and Claude D. Pepper centers), a testing site of the NIA-sponsored Interventions Testing Program, and a U.S. Department of Veterans Affairs Geriatric Research, Education and Clinical Center.